AstraZeneca halts lung trial as two cancer drugs show positive results
(Alliance News) - AstraZeneca PLC on Monday announced it is discontinuing the eVOLVE-Lung02 phase III trial after an independent review found its experimental drug volrustomig was unlikely to improve outcomes against the comparator treatment. Read More